Department of Medicine, Southern Älvsborg Hospital, Borås; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg.
Regional Cancer Center South East Sweden, Linköping; Department of Clinical and Experimental Medicine and Department of Oncology, Linköping University, Linköping.
Ann Oncol. 2015 Jun;26(6):1149-1154. doi: 10.1093/annonc/mdv159. Epub 2015 Apr 3.
In published radiotherapy trials, the failure rate in the control arm among patients with one to three positive nodes is high compared with that seen with modern adjuvant treatments. Therefore, the generalizability of the results has been questioned. The aim of the present study was to compare relative survival in breast cancer patients between two Swedish regions with screening mammography programs and adjuvant treatment guidelines similar with the exception of the indication of radiotherapy for patients with one to three positive nodes.
Between 1989 and 2006, breast cancer patients were managed very similarly in the west and southeast regions, except for indication for postoperative radiotherapy. In patients with one to three positive nodes, postmastectomy radiotherapy was generally given in the southeast region (89% of all cases) and generally not given in the west region (15% of all cases). For patients with one to three positive nodes who underwent breast-conserving surgery, patients in the west region had breast radiotherapy only, while patients in the southeast region had both breast and lymph nodes irradiated.
The 10-year relative survival for patients with one to three positive lymph nodes was 78% in the west region and 77% in the southeast region (P = 0.12). Separate analyses depending on type of surgery, as well as number of examined nodes, also revealed similar relative survival.
Locoregional postoperative radiotherapy has well-known side-effects, but in this population-based study, there was little or no influence of this type of radiotherapy on survival when one to three lymph nodes were involved.
在已发表的放疗试验中,与现代辅助治疗相比,1-3 个阳性淋巴结患者的对照组失败率较高。因此,其结果的普遍性受到质疑。本研究旨在比较瑞典两个地区的乳腺癌患者的相对生存率,这两个地区都有筛查性乳房 X 线照相术项目和相似的辅助治疗指南,但术后放疗的适应证除外。
1989 年至 2006 年间,在西部地区和东南部地区,乳腺癌患者的治疗方式非常相似,除了术后放疗的适应证。对于 1-3 个阳性淋巴结的患者,在东南部地区(所有病例的 89%)一般给予乳房根治术后放疗,而在西部地区(所有病例的 15%)一般不给予。对于接受保乳手术且有 1-3 个阳性淋巴结的患者,西部地区的患者仅接受乳房放疗,而东南部地区的患者则同时接受乳房和淋巴结照射。
在 1-3 个阳性淋巴结的患者中,10 年相对生存率在西部地区为 78%,在东南部地区为 77%(P=0.12)。根据手术类型以及检查的淋巴结数量进行的单独分析也显示了相似的相对生存率。
局部区域术后放疗有众所周知的副作用,但在这项基于人群的研究中,当 1-3 个淋巴结受累时,这种类型的放疗对生存的影响很小或没有。